# Microvesicles from quiescent and TGF-β1 stimulated hepatic stellate cells: Divergent impact on hepatic vascular injury

**Authors:** Jianlong Xie, Zhirong Ye, Xiaobing Xu, Anzhi Chang, Ziyi Yang, Qin Wu, Qunwen Pan, Yan Wang, Yanyu Chen, Xiaotang Ma, Huilai Miao, Palash Mandal, Palash Mandal, Palash Mandal

PMC · DOI: 10.1371/journal.pone.0306775 · PLOS ONE · 2024-07-10

## TL;DR

This study shows that microvesicles from resting liver cells protect blood vessels, while those from TGF-β1-stimulated cells worsen liver injury.

## Contribution

The study reveals divergent effects of microvesicles from quiescent versus TGF-β1-stimulated hepatic stellate cells on vascular injury.

## Key findings

- Quiescent HSC-MVs protect endothelial cells and reduce liver injury in rats.
- TGF-β1-stimulated HSC-MVs increase cytotoxicity and worsen liver damage.
- Effects are mediated through pathways like PI3K/AKT/VEGF and MEK/ERK/eNOS.

## Abstract

This study evaluated the effect of microvesicles(MVs) from quiescent and TGF-β1 stimulated hepatic stellate cells (HSC-MVs, TGF-β1HSC-MVs) on H2O2-induced human umbilical vein endothelial cells (HUVECs) injury and CCl4-induced rat hepatic vascular injury.

HUVECs were exposed to hydrogen peroxide (H2O2) to establish a model for vascular endothelial cell injury. HSC-MVs or TGF-β1HSC-MVs were co-cultured with H2O2-treated HUVECs, respectively. Indicators including cell survival rate, apoptosis rate, oxidative stress, migration, invasion, and angiogenesis were measured. Simultaneously, the expression of proteins such as PI3K, AKT, MEK1+MEK2, ERK1+ERK2, VEGF, eNOS, and CXCR4 was assessed, along with activated caspase-3. SD rats were intraperitoneally injected with CCl4 twice a week for 10 weeks to induce liver injury models. HSC-MVs or TGF-β1HSC-MVs were injected into the tail vein of rats. Liver and hepatic vascular damage were also detected.

In H2O2-treated HUVECs, HSC-MVs increased cell viability, reduced cytotoxicity and apoptosis, improved oxidative stress, migration, and angiogenesis, and upregulated protein expression of PI3K, AKT, MEK1/2, ERK1/2, VEGF, eNOS, and CXCR4. Conversely, TGF-β1HSC-MVs exhibited opposite effects. CCl4- induced rat hepatic injury model, HSC-MVs reduced the release of ALT and AST, hepatic inflammation, fatty deformation, and liver fibrosis. HSC-MVs also downregulated the protein expression of CD31 and CD34. Conversely, TGF-β1HSC-MVs demonstrated opposite effects.

HSC-MVs demonstrated a protective effect on H2O2-treated HUVECs and CCl4-induced rat hepatic injury, while TGF-β1HSC-MVs had an aggravating effect. The effects of MVs involve PI3K/AKT/VEGF, CXCR4, and MEK/ERK/eNOS pathways.

## Linked entities

- **Genes:** PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) [NCBI Gene 5290], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], MAP2K1 (mitogen-activated protein kinase kinase 1) [NCBI Gene 5604], MAP2K2 (mitogen-activated protein kinase kinase 2) [NCBI Gene 5605], MAPK3 (mitogen-activated protein kinase 3) [NCBI Gene 5595], MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594], VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422], NOS3 (nitric oxide synthase 3) [NCBI Gene 4846], CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852], PECAM1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 5175], CD34 (CD34 molecule) [NCBI Gene 947], Casp3 (caspase 3) [NCBI Gene 12367]
- **Proteins:** PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), AKT1 (AKT serine/threonine kinase 1), VEGFA (vascular endothelial growth factor A), NOS3 (nitric oxide synthase 3), CXCR4 (C-X-C motif chemokine receptor 4), PECAM1 (platelet and endothelial cell adhesion molecule 1), CD34 (CD34 molecule)
- **Chemicals:** H2O2 (PubChem CID 784), CCl4 (PubChem CID 5943)
- **Species:** Homo sapiens (taxon 9606), Rattus norvegicus (taxon 10116)

## Full-text entities

- **Genes:** TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, Pecam1 (platelet and endothelial cell adhesion molecule 1) [NCBI Gene 29583] {aka CD31, Pecam}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, Vegfa (vascular endothelial growth factor A) [NCBI Gene 83785] {aka VEGF-A, VEGF111, VEGF164, VPF, Vegf}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, Nos3 (nitric oxide synthase 3) [NCBI Gene 24600] {aka eNos}, MAPK3 (mitogen-activated protein kinase 3) [NCBI Gene 5595] {aka ERK-1, ERK1, ERT2, HS44KDAP, HUMKER1A, P44ERK1}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, Cd34 (CD34 molecule) [NCBI Gene 305081], Cxcr4 (C-X-C motif chemokine receptor 4) [NCBI Gene 60628], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, MAP2K2 (mitogen-activated protein kinase kinase 2) [NCBI Gene 5605] {aka CFC4, MAPKK2, MEK2, MKK2, PRKMK2}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, MAP2K1 (mitogen-activated protein kinase kinase 1) [NCBI Gene 5604] {aka CFC3, MAPKK1, MEK1, MEL, MKK1, PRKMK1}
- **Diseases:** vascular endothelial cell injury (MESH:D057772), liver fibrosis (MESH:D008103), Liver and hepatic vascular damage (MESH:D056486), hepatic inflammation (MESH:D007249), liver injury (MESH:D017093), cytotoxicity (MESH:D064420), fatty deformation (MESH:D008067)
- **Species:** Homo sapiens (human, species) [taxon 9606], Rattus norvegicus (brown rat, species) [taxon 10116]
- **Cell lines:** vein — Homo sapiens (Human), Finite cell line (CVCL_3722), HSC — Homo sapiens (Human), Skin squamous cell carcinoma, Cancer cell line (CVCL_2807)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11236151/full.md

## Figures

7 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11236151/full.md

## References

26 references — full list in the complete paper: https://tomesphere.com/paper/PMC11236151/full.md

---
Source: https://tomesphere.com/paper/PMC11236151